| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Less deemed dividend on subsidiary preferred stock attributable to the noncontrolling interests | 0 | 0 | - | - |
| Provision for income taxes | 0 | 0 | - | - |
| Revenue | 5 | 6 | 8 | 996 |
| Amortization of acquired intangible assets | 0 | 0 | - | 82 |
| Sales and marketing | 201 | 220 | 247 | 2,920 |
| General and administrative | 3,505 | 3,670 | 4,384 | 6,649 |
| Research and development | 1,088 | 790 | 787 | 1,542 |
| Cost of revenue | 55 | 41 | 36 | 1,381 |
| Total operating expenses | 4,849 | 4,721 | 5,454 | 12,574 |
| Operating loss | -4,844 | -4,715 | -5,446 | -11,578 |
| Gain on deconsolidation of subsidiary | 0 | - | - | 72,287 |
| Debt extinguishments loss - senior secured convertible notes | 0 | 0 | -58 | -1,403 |
| Debt modification expense | 0 | 0 | - | - |
| Interest income | 10 | 8 | 8 | 70 |
| Interest expense | 8 | 4 | 4 | 12 |
| Change in fair value - equity method investment | -4,382 | -10,643 | 21,004 | 407 |
| Change in fair value - senior secured convertible notes | 100 | 200 | 49 | -240 |
| Management fee income | 3,150 | 3,150 | 3,150 | 700 |
| Grant income | 163 | 80 | 18 | - |
| Other income (expense), net | -1,167 | -7,609 | 24,069 | 72,289 |
| Income (loss) before provision for income tax | -6,011 | -12,324 | 18,623 | 60,711 |
| Net income (loss) before noncontrolling interests | -6,011 | -12,324 | 18,623 | 60,711 |
| Net loss attributable to the noncontrolling interests | -628 | -403 | -345 | -3,688 |
| Net income (loss) attributable to pavmed inc | -5,383 | -11,921 | 18,968 | 64,399 |
| Less series b convertible preferred stock dividends earned | 90 | 88 | 86 | 83 |
| Less series c convertible preferred stock dividends earned | 470 | 481 | 398 | - |
| Less deemed dividend on series c convertible preferred stock | -385 | -818 | -789 | - |
| Net income (loss) attributable to pavmed inc. common stockholders | -6,328 | -13,308 | 17,695 | 64,316 |
| Net income (loss) per share attributable to pavmed inc. common stockholders basic | -0.29 | -0.74 | 1.28 | 6.43 |
| Net income (loss) per share attributable to pavmed inc. common stockholders diluted | -0.29 | -0.74 | 0.34 | 1.44 |
| Weighted average common shares outstanding, basic | 21,554,546 | 18,084,653 | 13,876,165 | 10,005,379 |
| Weighted average common shares outstanding, diluted | 21,554,546 | 18,084,653 | 52,496,401 | 44,475,638 |
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)